Why Generative AI Like ChatGPT Cannot Replace Physicians
There is a huge potential seen for artificial intelligence to provide clinical decision support. But there is also serious concern about how machine learning and clinical algorithms can introduce bias and perpetuate health inequity. Full Access: AMA
FDA Advisory Committee Votes in Support Of Favorable Benefit-Risk Profile For Neffy® Intranasal (IN) Epinephrine for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis. The committee’s thoughtful review of the data, and support of the potential for neffy to address significant unmet needs of the severe allergy community, if approved, is highly encouraging. Clinical data from more than 600 individuals demonstrate neffy’s absorption-enhancing nasal spray technology is comparable to injectable products in delivering potentially lifesaving epinephrine, but with unique advantages of being small, needle-free and conveniently sized. Full Access: ARS pharm
Association Between Early Return to School Following Acute Concussion and Symptom Burden at 2 Weeks Postinjury
In this cohort study, analysis of data collected from a multicenter sample of youth aged 5 to 18 years with concussion showed that older youth missed more days of school, on average, than younger youth. An early return to school was associated with a lower symptom burden at 14 days postinjury in the 8- to 12-year age group and 13- to 18-year age group. Full Access: JAMA
Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022
In 2022, approximately 1 in 5 older adults reported cost-related nonadherence. Real-time benefit tools may support medication cost conversations and cost-conscious prescribing, and patients are enthusiastic about their use. However, if disclosed prices are inaccurate, there is potential for harm through loss of confidence in the physician and nonadherence to prescribed medications. Full Access: JAMA
